141 related articles for article (PubMed ID: 37806560)
1. Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer.
Chen M; Xiao L; Jia H; Wang S; Jiang X; Lei X; Zhai Q; Lang J
Radiother Oncol; 2023 Dec; 189():109946. PubMed ID: 37806560
[TBL] [Abstract][Full Text] [Related]
2. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer.
Geng F; Guo J; Guo QQ; Xie Y; Dong L; Zhou Y; Liu CL; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Vaccine; 2019 Jul; 37(31):4382-4391. PubMed ID: 31202521
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Xia Q; Zhang FF; Geng F; Liu CL; Xu P; Lu ZZ; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Cancer Immunol Immunother; 2016 May; 65(5):613-24. PubMed ID: 27020681
[TBL] [Abstract][Full Text] [Related]
4. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model.
Geng F; Bao X; Dong L; Guo QQ; Guo J; Xie Y; Zhou Y; Yu B; Wu H; Wu JX; Zhang HH; Yu XH; Kong W
Oncoimmunology; 2020; 9(1):1747350. PubMed ID: 32363118
[TBL] [Abstract][Full Text] [Related]
6. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model.
Zhang FF; Qiao Y; Xie Y; Liu C; Wu H; Wu JX; Yu XH; Kong W; Zhang HH
Int Immunopharmacol; 2022 Nov; 112():109237. PubMed ID: 36152535
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Zhang HH; Kong W; Yu XH
Vaccine; 2016 Aug; 34(38):4526-4535. PubMed ID: 27498213
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Xie Y; Sun B; Wu H; Yu B; Kong W; Yu XH; Zhang HH
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):37-44. PubMed ID: 28004985
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models.
Chen M; Xu G; Fan M; Jia H; Xiao L; Lang J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4182-4193. PubMed ID: 31722575
[TBL] [Abstract][Full Text] [Related]
10. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
12. CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer.
Geng F; Dong L; Bao X; Guo Q; Guo J; Zhou Y; Yu B; Wu H; Wu J; Zhang H; Yu X; Kong W
Mol Ther Oncolytics; 2022 Sep; 26():304-313. PubMed ID: 36090474
[TBL] [Abstract][Full Text] [Related]
13. Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
Li X; Chen M; Lu W; Tang J; Deng L; Wen Q; Huang M; Deng R; Ye G; Ye W; Zhang D
Cancer Lett; 2021 Apr; 503():32-42. PubMed ID: 33482262
[TBL] [Abstract][Full Text] [Related]
14. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
16. Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters.
Pokhrel D; Badkul R; Jiang H; Kumar P; Wang F
J Appl Clin Med Phys; 2015 Jan; 16(1):5058. PubMed ID: 25679161
[TBL] [Abstract][Full Text] [Related]
17. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts.
Lee PJ; Sui YH; Liu TT; Tsang NM; Huang CH; Lin TY; Chang KP; Liu SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):254. PubMed ID: 35986369
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
